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Abstract
Introduction The c.1-34T>C 5' promoter region polymorphism
in cytochrome P450c17 (CYP17), a key enzyme in the
biosynthesis of estrogen, has been associated with breast
cancer risk, but most previous studies have been relatively small.
Methods We genotyped 1,544 incident cases of primary breast
cancer and 1,502 population controls, all postmenopausal
Swedish women, for the CYP17 c.1-34T>C polymorphism and
calculated odds ratios (ORs) and 95% confidence intervals
(CIs) from logistic regression models.
Results No overall association was found between CYP17 c.1-
34T>C and breast cancer risk, OR 1.0 (95% CI 0.8–1.3) for the
A2/A2 (CC) carriers compared to the A1/A1 (TT) carriers,
regardless of histopathology. We detected an interaction
between CYP17 c.1-34T>C and age at menarche (P = 0.026)
but regarded that as a chance finding as no dose-response
pattern was evident. Other breast cancer risk factors, including
menopausal hormone use and diabetes mellitus, did not modify
the overall results.
Conclusion It is unlikely that CYP17 c.1-34T>C has a role in
breast cancer etiology, overall or in combination with
established non-genetic breast cancer risk factors.
Introduction
Estrogen is a central factor in the etiology of breast cancer [1].
One of the key enzymes in the synthesis of sex hormones,
such as estrogens and androgens, is cytochrome P450c17
(CYP17). CYP17 catalyses the 17α-hydroxylation of pregne-
nolone and progesterone, and these intermediates are then
converted to dehydroepiandosterone and androstenedione by
the 17,20-lyase activity of the enzyme [2,3].
A single T (A1 allele) to C (A2 allele) base change in the 5' pro-
moter region of CYP17 (c.1-34T>C) has been suggested to
create an additional binding site for the transcription factor
Sp1 [4]. This could theoretically lead to increased levels of the
enzyme, but use of the extra binding site has not been con-
firmed experimentally [5]. Three groups have reported an
association of the A2 allele with increased breast cancer risk
[6-8] but others have failed to replicate those findings [5,9-
21]. A recent meta-analysis of 15 case-control studies did not
find any overall association [22] but this analysis was criticized
by Feigelson and colleagues [23], who found a borderline sig-
nificant association between the CYP17 polymorphism and
advanced breast cancer.
CI = confidence interval; CYP17 = cytochrome P450c17; DASH = dynamic allele-specific hybridization; OR = odds ratio; PCR = polymerase chain 
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In a population-based study about causes of postmenopausal
breast cancer, which included 1,544 cases and 1,502 con-
trols, we evaluated the association between CYP17  c.1-
34T>C and breast cancer risk among Swedish women. We
also explored potential interaction between genotype and
menopausal hormone use and diabetes mellitus as well as age
at menarche, age at menopause, age at first birth, parity and
body mass index.
Materials and methods
Founding study
This nation-wide case-control study included all Swedish
women, 50 to 74 years of age and resident in Sweden
between October 1993 and March 1995. During that period,
all incident cases of primary invasive breast cancer were iden-
tified at diagnosis through the six regional cancer registries in
Sweden, to which reporting of all malignant tumors is manda-
tory. Controls that matched the cases in 5-year age strata
were randomly selected from the Swedish Registry of Total
Population. Of the eligible cases and controls, 3,345 (84%)
and 3,454 (82%), respectively, participated in the study by
providing detailed information via questionnaires about meno-
pausal hormone use, reproductive history, and other lifestyle
factors. Results from the founding study have been published
[24-28].
Collection of biological samples
Only postmenopausal women with a first primary breast can-
cer without any previous malignancy (except carcinoma in situ
of the cervix or non-melanoma skin cancer) were eligible for
the present study. Premenopausal women and those with a
previous malignancy were excluded. From the eligible partici-
pants, we randomly selected 1,500 cases and 1,500 age-fre-
quency (in 5-year groups) matched controls. We were
interested in exploring the interaction between CYP17 c.1-
34T>C and menopausal hormones and diabetes mellitus as
both are breast cancer risk factors, possibly acting through
increased levels of exogenous and endogenous estrogens,
respectively. Thus, in order to increase statistical power in the
subgroup analyses, we further selected all remaining eligible
women (191 cases and 108 controls) that had used meno-
pausal hormones (estrogen only or any combination of estro-
gen and progestin) for at least 4 years and all women (110
cases and 104 controls) with self-reported diabetes mellitus.
In addition, 345 eligible controls from the founding study, orig-
inally selected for a parallel endometrial cancer study but who
fulfilled the inclusion criteria to the breast cancer study, were
added to our control sample. In total, we selected 1,801 cases
and 2,057 controls.
Paraffin-embedded, non-cancerous tissue samples were col-
lected for deceased breast cancer cases as well as for those
breast cancer cases that declined to donate blood but con-
sented to our use of the tissue. We obtained blood samples or
archived tissue samples for 1,322 and 247 breast cancer
patients, respectively, and blood samples from 1,524 controls.
Population-based participation rates (taking into account
those that did not participate in the founding study but could
have been selected) for cases and controls were 73% and
61%, respectively.
We isolated DNA from 3 ml of whole blood using a Wizard
Genomic DNA Purification Kit (Promega, Madison, WI, USA)
according to the manufacturer's instructions. From non-malig-
nant cells in paraffin-embedded tissue, we extracted DNA
using a standard phenol/chloroform/isoamyl alcohol protocol
[29]. The study was approved by the five Swedish Institutional
Review Boards and was performed in compliance with the
Helsinki Declaration.
Genetic analyses
We used two methods for CYP17 c.1-34T>C (rs743572)
genotyping: Multiplex fluorescent solid-phase minisequencing
[30]; and dynamic allele specific hybridization (DASH) [31].
Results from the two methods were validated with PCR-RFLP
[32]. Twenty-four percent of the samples were analysed with
both minisequencing and DASH, and the genotypes obtained
were identical. Primer and probe sequences and PCR reaction
conditions are given in Additional file 1. The PCR reactions
were performed on a Perkin Elmer GeneAmp 9700 system
(PerkinElmer Life And Analytical Sciences, Inc., Boston, MA,
USA).
Statistical analyses
Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using conditional logistic regression models with
the A1/A1 genotype as the reference group. We conditioned
the models on age (due to matching) and on duration of men-
opausal hormone use and self-reported diabetes mellitus (due
to our over-sampling scheme). The conditioning variables
were thus age (5-year age groups), menopausal estrogen only
use (never, <4 years or ≥4 years), menopausal estrogen and
progestin use (never, <4 years or ≥4 years) and self-reported
diabetes mellitus (yes or no). We chose to condition because
in the presence of interaction between any of the selection var-
iables and CYP17 genotype, estimates of the main effect of
CYP17 could be biased. We did not expect confounding by
other known breast cancer risk factors as they most likely
would be intermediates between the genetic variant and
breast cancer. We nevertheless included important breast
cancer risk factors as co-variates in the models and assessed
changes in the estimates of association between CYP17 gen-
otype and breast cancer to investigate if there were any indi-
cations of such interrelations. Breast cancer risk factors other
than menopausal hormone use that were analyzed for gene-
environment interaction were: Age at menarche (≤2 years,
>12–14 years or >14 years) and age at menopause (<49
years, 49–52 years or >52 years) (where 1st  category
included the 1st quartile of the data, 2nd category the 2nd and
3rd quartiles, and 3rd category the 4th quartile); age at first birthAvailable online http://breast-cancer-research.com/content/7/6/R890
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(≤24 years, 25–29 years or ≥30 years); parity (nulliparous, 1
child, 2 children or >2 children); and body mass index one year
prior to diagnosis (<25, 25 to <28, or ≥28). The last three
were categorized according to cut-offs that in previous studies
have been shown to be informative with regard to the varia-
bles' influence on breast cancer risk. The likelihood ratio test
and the Wald test statistic were used to test for interaction.
We performed all analyses using the SAS system (release
8.01; SAS Institute Inc., Cary, NC, USA).
Results
We obtained CYP17  c.1-34T>C genotypes from 1,544
breast cancer cases and 1,502 controls. Among the controls,
genotype frequencies were similar to previously published fre-
quencies in Caucasian populations [5,9-11,20,21] and did not
deviate from Hardy-Weinberg Equilibrium (P = 0.927). Geno-
type frequencies among the cases did not differ between
blood and tissue samples (P = 0.697).
We reproduced previously established breast cancer risk fac-
tor associations in this study population [24,25,33] (Table 1,
first column). The one exception was age at menarche, which
did not appear to be associated with overall breast cancer risk
in this study [25].
The CYP17 c.1-34T>C was not associated with other breast
cancer risk factors among the randomly selected controls
(Table 2).
We found no overall association between CYP17 c.1-34T>C
and breast cancer risk, regardless of histopathology (Table 3).
This negative result was not modified by menopausal hormone
use or diabetes mellitus (Table 3). We also did not detect any
Table 1
Breast cancer risk in relation to CYP17 genotype, stratified by breast cancer risk factors
All genotypes CYP17 genotype P for 
interaction
A1/A1 A1/A2 A2/A2
Cases/
controlsa
ORb (CI) Cases/
controlsa
ORb (CI) Cases/
controlsa
ORb (CI) Cases/
controlsa
ORb (CI)
Age at menarche (years)
≤12 314/262 1 (reference) 102/96 1 (reference) 138/128 1.1 (0.7–1.5) 74/38 1.9 (1.1–3.0)
>12–14 749/702 0.9 (0.7–1.1) 283/251 1.1 (0.8–1.5) 360/325 1.1 (0.8–1.5) 106/126 0.8 (0.6–1.0)
>14 300/258 1.0 (0.8–1.2) 107/94 1.1 (0.7–1.6) 152/126 1.2 (0.8–1.7) 41/38 1.1 (0.6–1.8) 0.026
Age at menopause (years)
<49 330/347 1 (reference) 145/123 1 (reference) 141/165 0.7 (0.5–1.0) 44/59 0.7 (0.4–1.1)
49–52 802/656 1.3 (1.1–1.6) 282/243 1.0 (0.7–1.3) 380/316 1.0 (0.8–1.4) 140/97 1.2 (0.9–1.8)
>52 357/323 1.2 (1.0–1.5) 119/117 1.0 (0.6–1.3) 184/150 1.1 (0.8–1.6) 54/56 0.8 (0.5–1.3) 0.062
Age at first birth (years)
≤24 616/639 1 (reference) 225/236 1 (reference) 310/315 1.1 (0.8–1.3) 81/88 1.0 (0.7–1.4)
25–29 414/388 1.1 (0.9–1.4) 145/144 1.1 (0.8–1.5) 187/171 1.2 (0.9–1.6) 82/73 1.2 (0.8–1.7)
≥30 242/187 1.4 (1.1–1.7) 100/67 1.6 (1.1–2.3) 107/89 1.3 (0.9–1.8) 35/31 1.1 (0.7–1.9) 0.752
Parity
Nulliparous 224/124 1 (reference) 79/41 1 (reference) 105/63 0.9 (0.5–1.5) 40/20 1.2 (0.6–2.3)
1 child 320/240 0.7 (0.5–0.9) 113/77 0.8 (0.5–1.2) 168/130 0.7 (0.4–1.0) 39/33 0.6 (0.3–1.1)
2 children 569/515 0.6 (0.4–0.7) 215/195 0.6 (0.4–0.9) 254/238 0.5 (0.4–0.8) 100/82 0.6 (0.4–1.0)
>2 children 386/459 0.5 (0.4–0.6) 143/175 0.4 (0.3–0.7) 184/207 0.5 (0.3–0.7) 59/77 0.4 (0.2–0.6) 0.792
Body mass index (kg/m2)
<25 716/669 1 (reference) 263/230 1 (reference) 337/329 0.9 (0.7–1.2) 116/110 0.9 (0.7–1.3)
25 to <28 371/377 1.0 (0.8–1.1) 141/137 0.9 (0.7–1.2) 170/181 0.9 (0.7–1.2) 60/59 0.9 (0.6–1.4)
≥28 403/278 145/116 1.2 (0.9–1.6) 198/121 1.4 (1.1–1.9) 60/41 1.4 (0.9–2.2) 0.657
aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. bAnalyses were conditioned on age 
(5-year age groups), menopausal estrogen only use (never, <4 years or ≥4 years), use of estrogen in combination with progestin (never, <4 years 
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association when we considered stage 1 (n = 389) and stage
2 or more advanced (n = 591) breast cancers separately (data
not shown). None of these findings were altered by restricting
the sample set to the randomly selected cases and controls or
by including other breast cancer risk factors as co-variates in
the logistic regression models.
In exploratory analyses, the A2/A2 genotype, compared to A1/
A1, was associated with an increased breast cancer risk in
women with age at menarche of 12 years or younger (OR 1.9,
95% CI 1.1–3.0; P for interaction = 0.026; Table 1). Further-
more, the A2 allele in carriers conferred a decreased risk in
women with menopause before 49 years of age; OR 0.7 (95%
CI 0.5–1.0) for heterozygotes and OR 0.7 (95% CI 0.4–1.1)
for homozygotes) compared to A1/A1. There was, however,
no dose-response pattern in these findings and we therefore
regarded them as being due to chance. Age at first birth, parity
or body mass index did not seem to modify the non-associa-
tion between CYP17 c.1-34T>C genotype and breast cancer
risk (Table 1). All estimates remained unaffected after we
restricted the analyses to the randomly selected cases and
controls.
Discussion
CYP17 c.1-34T>C was not associated with breast cancer risk
overall, a result that did not seem to be modified by menopau-
sal hormone use or diabetes mellitus. Incidentally, we detected
a statistically significant interaction between CYP17  c.1-
34T>C and age at menarche but regarded the finding as a
chance result as no dose-response pattern was evident.
Our population-based study is one of the largest published to
date, investigating the possible influence of CYP17 variation
on breast cancer risk. Retrieval of extensive information on
reproductive and lifestyle factors enabled us to test for gene-
environment interactions. Misclassification of genotypes
should be minimal as is indicated by the identical results from
replicate genotyping with two different methods, all blinded to
case-control status. Any genotype misclassification despite
these measures is unlikely to have been differential and would
consequently only bias our estimates towards the null.
Because pre- and postmenopausal breast cancer is con-
ceived to have differing causal mechanisms, these two types
of cancer are often investigated separately. We were inter-
ested in potential interaction between CYP17 genotype and
menopausal hormone treatment, which motivated our restrict-
ing the study population to postmenopausal women. Although
it would be interesting to know also if CYP17 genotype influ-
ences the risk of premenopausal breast cancer, had we
included both pre- and postmenopausal women, the study size
would have had to be increased to have the same power to
address our main hypotheses. We were also interested in
exploring the interaction with diabetes mellitus as insulin
resistance can lead to increased levels of plasma insulin, lower
levels of plasma sex hormone binding globulin and, conse-
quently, increased levels of free estrogen [34]. We thus over-
Table 2
Descriptive characteristics of postmenopausal breast cancer cases and controls by CYP17 c.1-34T>C genotype
CYP17 genotype
A1/A1 A1/A2 A2/A2
Characteristic Cases/
controlsa
Cases Controls Cases/
controlsa
Cases Controls Cases/
controlsa
Cases Controls
Genotype frequencies 550/488 36.7 36.5 711/638 47.4 47.7 238/212 15.9 15.8
Age (years)b 550/488 63.3 ± 6.5 63.0 ± 6.5 711/638 63.4 ± 6.5 62.9 ± 6.4 238/212 62.8 ± 6.6 63.2 ± 6.1
Age at menarche (years)b 492/441 13.5 ± 1.4 13.5 ± 1.4 650/579 13.6 ± 1.4 13.5 ± 1.4 221/202 13.2 ± 1.5 13.5 ± 1.3
Age at menopause (years)b 546/483 49.9 ± 3.8 50.1 ± 4.1 705/631 50.7 ± 3.2 50.0 ± 3.8 238/212 50.6 ± 3.2 50.2 ± 4.2
Age at first birth (years)b 470/447 25.4 ± 5.0 24.7 ± 4.6 604/575 25.1 ± 5.0 24.7 ± 4.7 198/192 25.6 ± 4.5 25.2 ± 4.9
Parityb 550/488 1.9 ± 1.2 2.3 ± 1.4 711/638 1.8 ± 1.2 2.1 ± 1.2 238/212 1.8 ± 1.2 2.2 ± 1.3
Body mass index (kg/m2)b 549/483 25.8 ± 4.1 25.8 ± 4.4 705/631 25.9 ± 4.2 25.2 ± 3.8 236/210 25.7 ± 4.4 25.3 ± 4.0
Duration of menopausal hormone use (years)c
0 390/370 70.9 75.8 469/473 66.0 74.1 165/154 69.3 72.6
<4 59/50 10.7 10.3 96/74 13.5 11.6 26/25 10.9 11.8
≥4d 101/68 18.4 13.9 146/91 20.5 14.3 47/33 19.8 15.6
Self-reported diabetes mellitusc,d 550/488 8.73 8.20 711/638 9.42 7.21 238/212 8.82 8.49
aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. bMeans ± standard deviation. 
cPercentages. dLong term users of menopausal hormones and women with diabetes mellitus were over-sampled.Available online http://breast-cancer-research.com/content/7/6/R890
R894
sampled menopausal hormone users and diabetics in the
design phase of the study so as to increase statistical preci-
sion in subgroup analyses. We explored only the effect of
CYP17 c.1-34T>C on breast cancer risk in this article, but 13
variants in 7 genes were genotyped in the current phase of the
study. Results from three of the studied genes in relation to
breast cancer risk have previously been published [35-37].
The lack of association between CYP17 c.1-34T>C and over-
all breast cancer risk in our study is in line with results from 14
previous studies – where 10 included only Caucasian women
– and a recent meta-analysis [5,9-22]. In contrast to Feigelson
and colleagues [8], we did not find any association between
this polymorphism and advanced breast cancer. Two groups
have reported an association between CYP17 genotype and
breast cancer risk in postmenopausal women [6,7]. All three
studies were performed in non-Caucasian populations.
A possible mechanism for the CYP17 c.1-34T>C polymor-
phism to influence breast cancer risk is through increased bio-
synthesis of and, thereby, increased levels of circulating
estrogen. Contrary to the predicted effect of the A2 allele, one
group found decreased CYP17 mRNA levels in A2 carriers
[38]. Studies regarding association of CYP17 c.1-34T>C and
circulating hormone levels as well as markers of hormonal sta-
tus (i.e. age at menarche or menopausal hormone use) have
recently been reviewed [39]. Increased estradiol levels have
been associated with the A2 allele in premenopausal women
[6,32] as well as in postmenopausal women [9,40], but three
groups did not report any significant changes in hormone lev-
els by genotype, two in postmenopausal women [17,41] and
one in premenopausal women [42]. Results from seven stud-
ies have indicated a moderate association between the A2
allele and earlier menarche [8,11,15,18,43-45], an associa-
tion that was not detected in our study, nor in five others
Table 3
Breast cancer risk in relation to CYP17 genotype, stratified by histopathological type, menopausal hormones or diabetes mellitus
CYP17 genotype P for 
interaction
A1/A1 A1/A2 A2/A2
Cases/controlsa ORb(CI) Cases/controlsa ORb(CI) Cases/controlsa ORb(CI)
All cancers 550/488 1 (reference) 711/638 1.0 (0.9–1.2) 238/212 1.0 (0.8–1.3)
Ductal cancers 420/488 1 (reference) 510/638 1.0 (0.8–1.1) 180/212 1.0 (0.8–1.3)
Lobular cancers 56/488 1 (reference) 90/638 1.3 (0.9–1.8) 24/212 1.1 (0.6–1.8)
Duration of 
menopausal 
hormone use(all 
cancers)
Never 390/370 1 (reference) 469/473 0.9 (0.8–1.1) 165/154 1.0 (0.8–1.3)
Any kind
<4 59/50 1 (reference) 96/74 1.2 (0.7–2.0) 26/25 1.0 (0.5–2.1)
≥4 101/68 1 (reference) 146/91 1.2 (0.8–1.9) 47/33 1.0 (0.6–1.7) 0.668
Estrogen only
<4 28/22 1 (reference) 43/33 1.1 (0.5–2.3) 7/11 0.6 (0.2–1.8)
≥4 39/23 1 (reference) 42/30 1.0 (0.5–2.1) 15/13 0.7 (0.3–1.9) 0.703
Estrogen + progestin
<4 42/41 1 (reference) 75/66 1.2 (0.7–2.1) 23/21 1.2 (0.6–2.5)
≥4 64/47 1 (reference) 108/62 1.3 (0.8–2.2) 34/20 1.2 (0.6–2.4) 0.723
Self-reported diabetes 
mellitus (all cancers)
No 502/448 1 (reference) 644/592 1.0 (0.8–1.2) 217/194 1.0 (0.8–1.3)
Yes 48/40 1 (reference) 67/46 1.3 (0.7–2.2) 21/18 1.1 (0.5–2.3) 0.259
aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. bAnalyses were conditioned on age 
(5-year age groups), menopausal estrogen only use (never, <4 years or ≥4 years), use of estrogen in combination with progestin (never, <4 years 
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[9,12,21,46,47]. Furthermore, previous investigators have
posited that CYP17 genotype may be associated with use of
menopausal hormones, an important risk factor for breast can-
cer, but results have been inconsistent [11,12,21,48-50]. We
found no such association in our data.
We identified an interaction with age at menarche, but consid-
ered it unlikely that the A2/A2 genotype would increase breast
cancer risk in women with age at menarche less than 13 years
without also moderately increasing risk in women with age at
menarche between 12 and 14 years. Instead, the A2/A2 gen-
otype decreased risk in the latter group, which is difficult to
explain biologically. A similar pattern was seen for the interac-
tion with age at menopause. To our knowledge, other groups
have not reported comparable findings and we therefore
believe the results to be caused by chance alone.
Conclusion
CYP17 c.1-34T>C does not appear to have any major influ-
ence on breast cancer risk. Despite this negative finding, it
would be prudent to investigate common variants covering the
entire CYP17 gene before concluding that this gene has no
role in breast cancer etiology.
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